ERIs Life Sciences

Ahmedabad, India Founded: 2007 • Age: 19 yrs Listed
Pharmaceutical formulations for chronic diseases are manufactured and studied.
Request Access
Report Incorrect Data
Page last updated

About ERIs Life Sciences

ERIs Life Sciences is a publicly listed company based in Ahmedabad (India) founded in 2007 by Amit Bakshi and Himanshu Shah. Pharmaceutical formulations for chronic diseases are manufactured and studied. ERIs Life Sciences has raised $43 million across 1 funding round from investors including ChrysCapital. The company has 3,560 employees. ERIs Life Sciences has completed 3 acquisitions, including Eris Oaknet Healthcare, Swiss Parenterals and Uth Healthcare. Its website eris.co.in draws about 35 thousand monthly visits. Its Indian entity Eris Lifesciences Limited reported revenue of ₹3,137 Cr. ERIs Life Sciences offers products and services including Branded Formulations and Patient Care Services. Its focus areas include Traditional Pharmaceuticals, Generics and Therapeutic Areas.

Company details

ERIs Life Sciences was founded in 2007 in Ahmedabad, India, within the pharmaceutical sector. Formulations for chronic diseases, particularly cardio-metabolic therapies, are produced. Expansion into dermatology, neuropsychiatry, womens health, and nephrology is underway. Studies are conducted, and patient care initiatives are offered to support diagnosis and management of chronic conditions across therapeutic areas.

Recognitions & Rankings of ERIs Life Sciences

India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#276
Valuation
₹20,400 Cr
2023 #316 2022 #331 2021 #304
  • Headquarters Ahmedabad, India
  • Employees 3,560
  • Founders Amit Bakshi, Himanshu Shah
  • Stage Public
  • Sectors
    Healthcare
  • Website category Finance · Investing
  • Email
    ••••••••
  • Website eris.co.in
  • Social LinkedIn Facebook Instagram YouTube
  • Legal Name Eris Lifesciences Ltd
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹16,626 Cr

    ERIS · NSE

  • Share Price
    ₹1,175.40

    -1.92% today

  • Revenue
    ₹3,129 Cr

    FY 2025-26 · +8.2% YoY

  • EBITDA
    ₹1,103 Cr

    Margin 35.2%

  • Net Profit
    ₹632 Cr

    FY 2025-26 · +81.0% YoY

  • P/E (TTM)
    20.5x

    P/B 3.7x

  • ROE
    19.2%

    ROCE 14.1%

  • Debt / Equity
    0.72

    Interest cover 23.4x

  • Total Equity Funding
    $43M (USD)

    in 1 rounds

  • Latest Funding Round
    $43M (USD), Series A

    Sep 2011

  • Investors
    ChrysCapital
  • Employee Count
    3,560
  • Investments & Acquisitions
    Eris Oaknet Healthcare

    & 2 more

Products & Services of ERIs Life Sciences

ERIs Life Sciences offers a comprehensive portfolio of products and services, including Branded Formulations and Patient Care Services.

Branded Formulations
Pharmaceuticals

Branded formulations are developed by Eris for chronic diseases, covering areas like cardio-metabolic therapies and emerging fields such as dermatology and nephrology.

Patient Care Services
Healthcare Services

Patient care services are offered by Eris, including diagnostic support for diabetes and cardiovascular conditions, along with initiatives for pain and gynaecological management.

Apps and channels of ERIs Life Sciences

its YouTube channel Eris Lifesciences Ltd has 581 subscribers and 2 videos.

Eris Lifesciences Ltd
YouTube 581 subscribers 2 videos Science & Technology
Open channel

Videos from ERIs Life Sciences

The most watched videos on ERIs Life Sciences's YouTube channel, Eris Lifesciences Ltd (581 subscribers). Click a video to play it here.

Eris Ka Salaam | Saluting Doctors & Healthcare Professionals
11.7K views
Eris Lifesciences: Happy Mother's Day 2021
822 views

More on Eris Lifesciences Ltd.

Funding Insights of ERIs Life Sciences

ERIs Life Sciences has successfully raised a total of $43M through 1 strategic funding round. The most recent funding activity was a Series A round of $43 million completed in September 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $43M
  • Total Rounds 1
  • Last Round Series A — $43M
  • First Round $43M

    (Sep 2011)

  • Investors Count 1

All 1 funding rounds of ERIs Life Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Sep 2011$43MSeries A––
ChrysCapital
Valuation history

1 investors in total: 1 institutional.

Investors in ERIs Life Sciences

ERIs Life Sciences has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include ChrysCapital.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
ChrysCapital
Investment firm focusing on private equity in sectors like financial services and healthcare.
1999chryscapital.com
Premium access

Investor details for ERIs Life Sciences

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Eris Lifesciences Limited (ERIs Life Sciences)

Eris Lifesciences Limited is the primary company behind ERIs Life Sciences. The board of Eris Lifesciences Limited currently have 7 directors; the longest-serving is Inderjeet Singh Negi, appointed in 2007. 12 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Inderjeet Singh Negi
DIN 01255388
Whole-time director25 Jan 200719 yrs 9 moEris Lifesciences Limited
Amit Indubhushan Bakshi
DIN 01250925
Managing Director27 Jan 200719 yrs 9 moEris Lifesciences Limited
Prashant Gupta
DIN 08122641
Director30 Apr 20188 yrs 5 moEris Lifesciences Limited
Kaushal Kamlesh Shah
DIN 01229038
Director04 Aug 20206 yrs 2 moEris Lifesciences Limited
Kalpana Vasantrai Unadkat
DIN 02490816
Director05 Jan 20215 yrs 9 moEris Lifesciences Limited
Vasudevan Sujesh
DIN 08240092
Director25 Jul 20224 yrs 3 moEris Lifesciences Limited
Vineet Varma
DIN 11600100
Director14 Mar 20267 moEris Lifesciences Limited

People of ERIs Life Sciences

16 people are tracked at ERIs Life Sciences (9 in leadership, 4 in board & advisors, 3 in team); the tracked headcount is 3,560.

NameRoleGroup
Amit Bakshi
Co-Founder & Managing DirectorLeadership
Himanshu Shah
Co-FounderLeadership
Krishnakumar Vaidyanathan
Executive Director & Chief Operating OfficerLeadership
Sreenivasulu Syanam
Head Of QCLeadership
Inderjeet Singh Negi
Executive DirectorLeadership
Dr.mukund Ks Cio Certified
AVP & Head ITLeadership
Gaurav Pawar
Head Of Quality AssuranceLeadership
Ramprasad Bhat
Vice President Strategy And Special Projects HEAD Oncology DivisionLeadership
Praveen Veeramalla
Vice President & Head Of QualityLeadership
Vijaya Sampath
Independent DirectorBoard & advisors
Rajeev Dalal
Independent DirectorBoard & advisors
Kalpana Unadkat
Independent DirectorBoard & advisors
Prashant Gupta
Independent DirectorBoard & advisors
Swaraj Singh
Procurement ManagerTeam
Ravinder Ojha
Senior Regulatory Affairs SpecialistTeam
Naresh Adepu
Group Product ManagerTeam
Premium access

Complete people profiles for ERIs Life Sciences

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of ERIs Life Sciences

ERIs Life Sciences is a publicly listed company on the NSE with ticker symbol ERIS in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date29 Jun 2017
  • Listed onBSE: 540596 · NSE: ERIS
  • Listed entityEris Lifesciences Ltd
  • Exchange sectorHealth technology
  • ISININE406M01024
  • Share price₹1,149.60 (-0.02% on the day) · 2026-10-14
  • Market capitalisation₹15,956 Cr
  • Price to earnings24.5
  • EPS (diluted, trailing year)₹46.96
  • Dividend yield0.63%
  • Volume (last session)23,505

Financials of ERIs Life Sciences

Exchange-reported figures of Eris Lifesciences Limited, the listed company behind ERIs Life Sciences (NSE: ERIS).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹3,129 Cr
+8.1% YoY
EBITDA
₹1,103 Cr
+8.4% YoY
Profit After Tax
₹632 Cr
+81.0% YoY
Net Worth
₹3,903 Cr
+36.7% YoY
Total Assets
₹6,346 Cr
+8.9% YoY
Total Debt
₹2,359 Cr
-4.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue3,1292,8942,0561,7331,3471,2121,074
Revenue growth+8.2%+40.7%+18.7%+28.6%+11.2%+12.8%-
EBITDA1,1031,017675537485431368
EBITDA margin+35.2%+35.2%+32.8%+31.0%+36.0%+35.5%+34.3%
Profit before tax639489431405442394331
Net profit632349389378408353292
Net profit margin+20.2%+12.1%+18.9%+21.8%+30.3%+29.1%+27.2%
EPS (₹)44.7325.8328.8328.1029.8826.1621.84
Balance sheet
Total assets6,3465,8306,0643,1602,0301,6211,337
Net worth3,9032,8542,5862,1961,9081,5761,296
Total debt2,3592,4782,78187784.416.780.00
Cash & bank67.302231,40158.4652.3338.2867.33
Net working capital8255331,860485332252240
Cash flow
Cash from operations5381,065486292378375271
Cash from investing(369)(78.20)(1,828)(975)(320)(323)123
Cash from financing(314)(881)1,380688(44.70)(82.40)(335)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue892873757807792773705727
Revenue growth (YoY)+12.6%+13.0%+7.3%+11.0%+6.9%+7.4%--
Other income3.202.392.230.143.093.588.014.22
EBITDA273296272264288277252250
EBITDA margin+30.6%+34.0%+36.2%+33.0%+36.5%+35.9%+35.9%+34.7%
Depreciation73.4272.0769.5770.3469.0870.5177.2581.00
Interest46.4246.6545.6248.8249.5548.6854.2857.17
Profit before tax156179159145173161129116
Tax(31.23)36.17(120)36.5238.2036.0026.5229.30
Net profit18714327910913412510287.06
EPS (₹)13.2510.2620.577.318.818.646.896.15
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,8221,6981,5281,3401,2161,1091,020
Revenue growth+7.3%+11.1%+14.0%+10.3%+9.6%+8.7%-
EBITDA598487454505484417356
EBITDA margin+32.8%+28.7%+29.7%+37.7%+39.8%+37.7%+34.9%
Profit before tax362120329437459389324
Net profit25474.56297393419348287
Net profit margin+13.9%+4.4%+19.4%+29.3%+34.5%+31.4%+28.1%
EPS (₹)17.625.6822.0429.2730.6925.8221.45
Balance sheet
Total assets5,3444,8195,1392,6071,9841,6101,334
Net worth3,1952,5152,5242,2221,9191,5751,300
Total debt2,1012,2452,5723170.000.000.00
Cash & bank27.7692.461,29747.6546.1132.6664.95
Net working capital5892241,666346314229226
Cash flow
Cash from operations564702336322369395265
Cash from investing(694)(359)(2,492)(513)(268)(348)127
Cash from financing71.06(310)2,160194(88.42)(81.13)(334)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue482444277315650579405400
Revenue growth (YoY)-25.9%-23.3%-31.5%-21.1%+49.0%+26.7%--
Other income19.2426.3826.9725.0723.5922.6816.757.79
Total expenses335324256253354362284300
EBITDA14712021.7862.6829721612199.57
EBITDA margin+31.2%+27.6%+8.1%+20.4%+46.6%+38.1%+30.6%+25.5%
Depreciation40.8839.9838.8238.6639.3037.6043.3846.68
Interest42.0642.1642.7045.2046.5045.1453.1654.65
Profit before tax83.5164.14(32.77)3.8923515641.186.03
Tax(45.64)15.84(24.17)0.8085.1056.2710.714.25

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 28 Oct 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue892873757807792773705727
Revenue growth (YoY)+12.6%+13.0%+7.3%+11.0%+6.9%+7.4%--
Other income3.202.392.230.143.093.588.014.22
EBITDA273296272264288277252250
EBITDA margin+30.6%+34.0%+36.2%+33.0%+36.5%+35.9%+35.9%+34.7%
Depreciation73.4272.0769.5770.3469.0870.5177.2581.00
Interest46.4246.6545.6248.8249.5548.6854.2857.17
Profit before tax156179159145173161129116
Tax(31.23)36.17(120)36.5238.2036.0026.5229.30
Net profit18714327910913412510287.06
EPS (₹)13.2510.2620.577.318.818.646.896.15
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue3,1292,8942,0561,7331,3471,2121,074
Revenue growth+8.2%+40.7%+18.7%+28.6%+11.2%+12.8%-
Other income7.8418.4223.8211.1526.098.7115.40
Total expenses2,0271,8761,3811,196862781706
Employee cost557505404346250229206
EBITDA1,1031,017675537485431368
EBITDA margin+35.2%+35.2%+32.8%+31.0%+36.0%+35.5%+34.3%
Depreciation28031518311764.7142.9950.26
Interest19323184.8026.174.221.982.30
Profit before tax639489431405442394331
Tax(8.97)11434.2230.4836.4039.3634.85
Net profit632349389378408353292
Net profit margin+20.2%+12.1%+18.9%+21.8%+30.3%+29.1%+27.2%
EPS (₹)44.7325.8328.8328.1029.8826.1621.84
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital13.8513.6213.6013.6013.5913.5813.58
Reserves & surplus3,8892,8412,5732,1821,8941,5631,283
Shareholders' funds (net worth)3,9032,8542,5862,1961,9081,5761,296
Minority interest(7.01)41763624.69(0.11)0.000.00
Secured loans2,3092,4211,75383045.000.000.00
Unsecured loans49.1456.491,02846.7139.416.780.00
Total debt2,3592,4782,78187784.416.780.00
Total liabilities6,3465,8306,0643,1602,0301,6211,337
Assets
Gross block6,1626,0614,7732,8431,0921,006984
Net block5,1885,3064,3192,568918854875
Capital work in progress17167.0119.6721.7226.991.564.37
Investments61.5667.0015.5536.7052029477.99
Inventories43733518913111894.4769.48
Sundry debtors680459422293161140157
Cash & bank balances67.302231,40158.4652.3338.2867.33
Loans & advances355205290252197143111
Total current assets1,5401,2212,302735528417405
Total current liabilities714688442250196165165
Net working capital8255331,860485332252240
Total assets6,3465,8306,0643,1602,0301,6211,337
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash20094.2556.0250.8736.9267.317.50
Net cash from operating activities5381,065486292378375271
Net cash from investing activities(369)(78.20)(1,828)(975)(320)(323)123
Net cash from financing activities(314)(881)1,380688(44.70)(82.40)(335)
Net change in cash(145)10538.135.1513.96(30.39)59.81
Closing cash67.302231,40158.4652.3338.2867.33
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+8.2%+40.7%+18.7%+28.6%+11.2%+12.8%-
EBITDA growth+8.4%+50.7%+25.7%+10.7%+12.6%+16.9%-
PBT growth+30.6%+13.3%+6.6%-8.5%+12.1%+19.1%+4.4%
Net income growth+81.0%-10.3%+3.0%-7.3%+15.6%+20.8%-
Revenue CAGR (3Y)+21.8%+29.0%+19.3%+17.3%+11.1%+12.3%+12.7%
EBITDA CAGR (3Y)+27.1%+28.0%+16.1%+13.4%+12.0%+10.2%+11.0%
Profitability & leverage
Net income margin+20.7%+13.0%+19.3%+21.6%+30.1%+29.3%+27.6%
Return on capital employed+14.1%+13.3%+12.1%+16.7%+24.5%+26.8%+24.8%
Return on net worth+19.2%+13.8%+16.6%+18.2%+23.3%+24.7%+24.2%
Debt / equity0.720.970.760.230.030.000.07
Long-term debt / equity0.570.500.290.190.020.000.00
Interest cover23.4032.9617.226.241.000.510.72
Efficiency & per share
Fixed asset turnover0.510.530.540.881.281.221.18
Inventory turnover8.1111.0512.8313.9012.6914.7814.12
Debtors turnover5.506.575.757.648.948.158.92
EPS (₹)44.7325.8328.8328.1029.8826.1621.84
Dividend per share (₹)7.217.350.007.356.015.502.87
Book value per share (₹)281.78209.57190.16161.48140.36116.1095.47
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue482444277315650579405400
Revenue growth (YoY)-25.9%-23.3%-31.5%-21.1%+49.0%+26.7%--
Other income19.2426.3826.9725.0723.5922.6816.757.79
Total expenses335324256253354362284300
EBITDA14712021.7862.6829721612199.57
EBITDA margin+31.2%+27.6%+8.1%+20.4%+46.6%+38.1%+30.6%+25.5%
Depreciation40.8839.9838.8238.6639.3037.6043.3846.68
Interest42.0642.1642.7045.2046.5045.1453.1654.65
Profit before tax83.5164.14(32.77)3.8923515641.186.03
Tax(45.64)15.84(24.17)0.8085.1056.2710.714.25
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,8221,6981,5281,3401,2161,1091,020
Revenue growth+7.3%+11.1%+14.0%+10.3%+9.6%+8.7%-
Other income98.3135.5134.8317.2628.9910.0014.73
Total expenses1,2241,2111,074835732691665
Employee cost341362332253220207192
EBITDA598487454505484417356
EBITDA margin+32.8%+28.7%+29.7%+37.7%+39.8%+37.7%+34.9%
Depreciation15418210264.6651.4637.6444.88
Interest18022057.4220.813.050.941.97
Profit before tax362120329437459389324
Tax11842.6629.1238.9141.3438.2832.32
Net profit25474.56297393419348287
Net profit margin+13.9%+4.4%+19.4%+29.3%+34.5%+31.4%+28.1%
EPS (₹)17.625.6822.0429.2730.6925.8221.45
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital13.8513.6213.6013.6013.5913.5813.58
Reserves & surplus3,1822,5012,5102,2081,9051,5621,286
Shareholders' funds (net worth)3,1952,5152,5242,2221,9191,5751,300
Secured loans1,9102,0702,4333170.000.000.00
Unsecured loans1911741390.000.000.000.00
Total debt2,1012,2452,5723170.000.000.00
Total liabilities--5,1392,6071,9841,6101,334
Assets
Gross block2,9132,8751,8111,095778717696
Net block2,3532,4121,516898642584601
Capital work in progress0.000.270.610.342.981.564.37
Investments1,4149911,619997778531320
Inventories12119191.6363.7084.7964.8565.46
Sundry debtors307236240229138114141
Cash & bank balances27.7692.461,29747.6546.1132.6664.95
Loans & advances567108248182212162104
Total current assets1,0236281,877522480373375
Total current liabilities434404211176166144149
Net working capital5892241,666346314229226
Total assets5,3444,8195,1392,6071,9841,6101,334
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash84.3451.9347.4844.7031.3564.936.46
Net cash from operating activities564702336322369395265
Net cash from investing activities(694)(359)(2,492)(513)(268)(348)127
Net cash from financing activities71.06(310)2,160194(88.42)(81.13)(334)
Net change in cash(59.16)32.414.452.7813.36(33.58)58.47
Closing cash27.7692.461,29747.6546.1132.6664.95
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+7.3%+11.1%+14.0%+10.3%+9.6%+8.7%-
EBITDA growth+22.8%+7.2%-10.2%+4.4%+16.0%+17.4%-
PBT growth+201.6%-63.5%-24.7%-4.7%+17.9%+20.2%+3.8%
Net income growth+240.0%-74.9%-24.4%-6.2%+20.3%+21.4%-
Revenue CAGR (3Y)+10.8%+11.8%+11.3%+9.5%+10.7%+13.4%+12.7%
EBITDA CAGR (3Y)+5.8%+0.2%+2.8%+12.4%+13.2%+9.7%+9.5%
Profitability & leverage
Net income margin+13.4%+4.6%+19.6%+29.7%+34.3%+31.6%+28.6%
Return on capital employed+10.7%+6.8%+10.0%+19.9%+25.7%+26.5%+24.2%
Return on net worth+8.6%+3.1%+12.6%+19.2%+23.9%+24.4%+23.7%
Debt / equity0.760.960.610.080.000.000.07
Long-term debt / equity0.430.430.150.050.000.000.00
Interest cover40.5072.2616.344.720.710.250.63
Efficiency & per share
Fixed asset turnover0.630.731.051.431.631.571.64
Inventory turnover11.6612.0519.6818.0516.2517.0214.56
Debtors turnover6.717.166.517.319.678.719.42
EPS (₹)17.625.6822.0429.2730.6925.8221.45
Dividend per share (₹)7.217.350.007.356.015.502.87
Book value per share (₹)230.72184.65185.59163.39141.11116.0395.72

Investments & Acquisitions by ERIs Life Sciences

ERIs Life Sciences has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Eris Oaknet Healthcare, Swiss Parenterals and Uth Healthcare.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Swiss Parenterals
Contract development and manufacturing for pharmaceutical products are offered.
swiss.inAhmedabad, India1986Feb 2024$77M
Eris Oaknet Healthcare
Pharmaceutical products are manufactured by Eris Oaknet Healthcare in India.
oaknethealthcare.comMumbai, India2011May 2022$85M
Uth Healthcare
Distributor of diabetes, obesity, and other drugs
uthhealthcare.comPune, India2011Oct 2017$1.97M
Premium access

Complete acquisition details for ERIs Life Sciences

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of ERIs Life Sciences

6 dated milestones of ERIs Life Sciences across 17 years, from founding to its latest funding, stage changes and deals.

  1. Founded ERIs Life Sciences is founded.
  2. Funding First funding round of $43.0M.
  3. IPO Lists on the stock exchange (IPO).
  4. Acquisition Acquires Uth Healthcare.
  5. Acquisition Acquires Eris Oaknet Healthcare.
  6. Acquisition Acquires Swiss Parenterals.

Web traffic of ERIs Life Sciences

The website of ERIs Life Sciences (eris.co.in) receives about 35.5K visits a month and ranks #776,236 among all websites worldwide, #7,429 in Investing.

  • Monthly visits
    35.5K

    ▲ 10% vs previous month

  • Unique visitors
    14.7K

    per month

  • Global rank
    #776,236

    among all websites

  • Category rank
    #7,429

    Finance · Investing

Similar websites

Websites whose visitors overlap most with ERIs Life Sciences. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
ftindia.com
ftindia.com
100%
–
Edelweiss Finance
edelweissfin.com
100%
35.9K#752,756View details
Wellness Forever
wellnessforever.com
99%
480.8K#74,529View details
Sigachi
sigachi.com
99%
16.7K#811,695View details
edenred.co.in
edenred.co.in
60%
–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 8 similar websites and full traffic analytics for ERIs Life Sciences

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 8 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as ERIs Life Sciences (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M5,180
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.21 B25,870
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Eris Life Sciences

Eris Lifesciences: Macquarie on Eris Lifesciences Maintains Outperform, Target Price ₹1,575; Q2FY27 revenue and EBITDA were 2% above estimates, while adjusted PAT was broadly in line. Domestic revenue grew 14.1% YoY, or 16.5% excluding the portfolio licensed to Zorvia Healthcare, led by OAD, cardiac, VMN and diabetes growth; international revenue was flat YoY but rose around 15% QoQ.
Exchange Update • 1 day ago
ERIS: Q2 CONS NET PROFIT 1.84B RUPEES VS 1.2B (YOY); EST 1.45B
Exchange Update • 2 days ago
ERIS: Q2 EBITDA 3.1B RUPEES VS 2.9B (YOY); Q2 EBITDA MARGIN 34.67% VS 36.37% (YOY)
Exchange Update • 2 days ago
ERIS: Q2 REVENUE 8.9B RUPEES VS 7.9B (YOY)
Exchange Update • 2 days ago
Eris Lifesciences COO V Krishnakumar steps down, set to join Biological E
Moneycontrol • 1 month ago
Neutral Eris Lifesciences; target of Rs 1435: Motilal Oswal
Moneycontrol • 3 months ago
Buy Eris Lifesciences; target of Rs 1700: Prabhudas Lilladher
Moneycontrol • 3 months ago
ERIS: Strong Q1 growth in revenue and insulin franchise, with margin recovery expected from Q3
Quartr • 3 months ago
Eris Lifesciences Q1 PAT rises 14.5% on strong domestic formulations growth; insulin, GLP-1 businesses shine
Moneycontrol • 3 months ago
ERIS: Q1 FY27 saw robust revenue and profit growth, major acquisition, and interim dividend declaration
Quartr • 3 months ago
Premium access

Complete news archive for ERIs Life Sciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about ERIs Life Sciences

ERIs Life Sciences was founded in 2007 and raised its 1st funding round 4 years after it was founded.

ERIs Life Sciences is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.

ERIs Life Sciences is a funded company, having raised a total of $43M across 1 funding round to date. The company's 1st funding round was a Series A of $43M, raised on Sep 2011.

ERIs Life Sciences has 3,560 employees.

The primary company behind ERIs Life Sciences, Eris Lifesciences Limited, reported revenue of ₹3,137 Cr for FY 2026, up 8% year on year.

ERIs Life Sciences was founded in 2007 in Ahmedabad, India, within the pharmaceutical sector. Formulations for chronic diseases, particularly cardio-metabolic therapies, are produced. Expansion into dermatology, neuropsychiatry, womens health, and nephrology is underway. Studies are conducted, and patient care initiatives are offered to support diagnosis and management of chronic conditions across therapeutic areas.

ERIs Life Sciences offers Branded Formulations and Patient Care Services.

Yes, ERIs Life Sciences is publicly traded on NSE under the ticker symbol ERIS.

ERIs Life Sciences has made 3 acquisitions, including Eris Oaknet Healthcare, Swiss Parenterals, and Uth Healthcare.

ERIs Life Sciences has 1 investor. Key investors include ChrysCapital.

ERIs Life Sciences operates through Eris Lifesciences Limited.

The legal entities of ERIs Life Sciences currently have 9 directors, including Kalpana Vasantrai Unadkat, Sachin Shah, Vasudevan Sujesh and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available